Literature DB >> 10882578

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

A U Neumann1, N P Lam, H Dahari, M Davidian, T E Wiley, B P Mika, A S Perelson, T J Layden.   

Abstract

Many studies have shown that patients infected with hepatitis C virus (HCV) of genotype 2 have better response to interferon (IFN)-alpha treatment than genotype 1 patients; however, the mechanisms responsible for this difference are not understood. In this study, viral dynamics during high-dose IFN induction treatment were compared between the genotypes. Patients in each group received 10 MU of IFN-alpha2b for 14 days, and HCV RNA levels were frequently determined. Nonlinear fitting, both individually for each patient and using a mixed-effects approach, of the viral kinetic data to a mathematical model of the IFN effect on HCV infection was performed. The antiviral effectiveness of IFN in blocking virus production, the free virion clearance rate, and the HCV-infected cell death rate were all significantly higher for genotype 2 patients than for genotype 1 patients. Thus, the better response rate of patients infected with HCV genotype 2 is multifactorial. This is the first finding of a difference in viral dynamics between subtypes of the same virus and demonstrates the importance of subtype-specific virus-host-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882578     DOI: 10.1086/315661

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  52 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

Review 3.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

4.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

5.  Hepatitis C Viral Kinetics in Special Populations.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2008

6.  Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.

Authors:  S Zhao; D Cheng; E Liu; H Yu; H Yang; X Xue; Y Chu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

Review 7.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

8.  Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

Authors:  E Shudo; R M Ribeiro; A S Perelson
Journal:  J Viral Hepat       Date:  2008-05       Impact factor: 3.728

9.  Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.

Authors:  Fabrizio Mecenate; Adriano M Pellicelli; Giuseppe Barbaro; Mario Romano; Angelo Barlattani; Ettore Mazzoni; Maria Elena Bonaventura; Lorenzo Nosotti; Pasquale Arcuri; Antonio Picardi; Giorgio Barbarini; Cecilia D'Ambrosio; Amerigo Paffetti; Arnaldo Andreoli; Fabrizio Soccorsi
Journal:  BMC Gastroenterol       Date:  2010-02-19       Impact factor: 3.067

Review 10.  Managing chronic hepatitis C in the difficult-to-treat patient.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Liver Int       Date:  2007-12       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.